DoD Peer Reviewed Orthopaedic, Clinical Trial Award | W81XWH 21 PRORP CTA

Opportunity Information: Apply for W81XWH 21 PRORP CTA

The DoD Peer Reviewed Orthopaedic Research Program (PRORP) Clinical Trial Award (CTA) is a Department of Defense funding opportunity meant to move orthopaedic solutions into real-world patient testing quickly. Its purpose is to support the rapid start and execution of human clinical trials that could materially improve the treatment or management of orthopaedic injuries affecting Service members and Veterans, especially combat-related injuries and non-battle injuries that still significantly reduce unit readiness and delay return to duty or work. A central theme of the award is practicality and near-term impact: applicants are pushed to explain how their trial could help deliver effective care closer to the point of injury and/or shorten the timeline for functional recovery and return to duty/work.

This mechanism is strictly limited to clinical trials in human subjects, not animal work, not bench studies, and not general clinical research that does not prospectively assign participants to an intervention. In this announcement, a clinical trial is defined in the standard federal way: a research study where one or more human subjects are prospectively assigned to one or more interventions (including placebo or other controls) to evaluate effects on biomedical or behavioral health-related outcomes. The program explicitly contrasts the CTA with the PRORP Clinical Translational Research Award (CTRA): the CTRA can support broader clinical research, while the CTA is only for studies that meet the clinical trial definition. Projects can range from smaller, early stage trials (pilot studies, first-in-human efforts, phase 0 style feasibility trials) up through larger trials designed to determine efficacy in relevant patient populations. The types of interventions the DoD is willing to support are broad as long as they are trial-ready, including new products, drugs or biologics, medical devices, clinical guidance, and emerging approaches or technologies.

Funding is structured around Research Levels. All applications, regardless of focus area, are eligible for Research Level 1. A specific enhanced pathway, the Rehabilitation Option (Research Level 2), is available only for applications within the "Translation of Early Findings - Soft Tissue Trauma" focus area. This option is meant to incentivize truly integrated interdisciplinary work between surgical/trauma clinicians and rehabilitation professionals. Under this model, the project must combine surgical strategies (for example, reconstruction and repair and/or the use of biologics, pharmaceuticals, or devices aimed at restoring tissue architecture and function) with rehabilitative strategies (approaches intended to restore function and independence after injury). The expectation is that the integration creates added value beyond what surgery or rehab would accomplish in isolation. Applicants must spell out the rehabilitation strategy and the relevant standard of care, and trials that follow patients across the continuum of care are encouraged. To ensure the collaboration is real, the team must include at least one investigator with orthopaedic rehabilitation expertise and at least one clinician specializing in orthopaedic or trauma care, and letters of collaboration from both are required for this option.

Because the program is designed to test interventions in humans, it places strong emphasis on regulatory readiness and compliance. If a proposed trial uses a drug that is not FDA-approved for the intended investigational use, an Investigational New Drug (IND) application under 21 CFR 312 may be required. If a device is being studied, an Investigational Device Exemption (IDE) under 21 CFR 812 may be required (or the device may qualify for an abbreviated IDE). In either case, it is on the applicant to provide documentation from the Institutional Review Board (IRB) of record or from the FDA indicating whether an IND/IDE is or is not required. When an IND or IDE is required, it must be submitted to the FDA within 6 months of the award date, and it must match the specific product/device and the indication being tested (meaning the submission cannot be for a different derivative or modified version than what the trial will actually use). If international sites are involved for investigational products, the relevant host-country regulatory applications must also be filed within 6 months. The government explicitly reserves the right to withdraw funding if required regulatory submissions are not made on time, underscoring that this award is intended for trials that are operationally ready to launch.

The announcement lays out a detailed picture of what a competitive, fundable trial should look like. Preliminary data relevant to the proposed clinical trial is required, and the trial is expected to begin within 12 months after the award date, reinforcing the "rapid implementation" goal. The intervention being tested needs to have credible potential for significant impact on military and Veteran outcomes related to orthopaedic injuries and readiness. The trial must be grounded in a sound scientific rationale supported by careful reasoning and a critical review of existing literature, rather than speculative claims. Practical feasibility is treated as essential: applicants must show access to a suitable patient population, explain how accrual goals will be met, and discuss how standards of care could influence enrollment or outcomes. They must also document access to the drug/device/materials for the duration of the study and address product quality and stability in a way that matches applicable FDA manufacturing expectations (such as GMP and Quality System Regulation standards depending on product type and development phase).

Operational trial rigor is another major emphasis. Applications are expected to present clear objectives and appropriate endpoints or outcome measures, and trials must comply with Good Clinical Practice (GCP). A solid statistical foundation is required, including an explicit statistical analysis plan, appropriate statistical expertise on the team, and a power analysis that justifies sample size projections and demonstrates the study can answer its primary questions. Applicants must also provide a data management plan and use an appropriate database to protect data integrity; if the trial is FDA-regulated, a 21 CFR Part 11-compliant database and appropriate data standards are required. In addition, the program expects a safety management plan (including pharmacovigilance when applicable), and a clinical monitoring plan that explains how the study will be monitored for GCP compliance. The announcement also calls out the importance of having study coordinator support to shepherd the protocol through local IRB and other regulatory processes, coordinate across multiple sites if needed, and manage participant recruitment.

The DoD also cares about what happens after the trial ends, not just whether it gets published. Applications must include a Transition Plan describing how the product or approach will move to the next clinical trial phase and/or toward market delivery after successful completion. Strong institutional support or an industry partnership is viewed as important, and when applicable the application should show a commitment to serve as the FDA regulatory sponsor and fulfill sponsor responsibilities (notably those described for drugs in 21 CFR 312, Subpart D). On the transparency and public accountability side, funded trials must register on ClinicalTrials.gov prior to initiating the study, and they are required to post the IRB-approved informed consent form on a publicly available federal website in accordance with federal requirements referenced in 32 CFR 219.

Mechanically, awards under this announcement are issued as assistance agreements, meaning the government is supporting a public purpose rather than purchasing a deliverable for direct government use. Depending on the expected level of DoD involvement during performance, the award may be a grant (when no substantial involvement is anticipated, consistent with 31 USC 6304) or a cooperative agreement (when substantial involvement is anticipated, consistent with 31 USC 6305). The final choice between grant and cooperative agreement, along with the project start date, is determined during negotiations, and cooperative agreements will spell out the nature of the government involvement (such as collaboration or participation in aspects of the effort).

Budget and scale are clearly bounded. Total costs for the entire period of performance are capped at $2.25 million for Research Level 1 and $2.75 million for Research Level 2. For FY21, the program anticipated allocating roughly $9 million to fund about four Research Level 1 awards and about $5.5 million to fund two Research Level 2 awards, for a total expectation of six awards. Eligibility is described as unrestricted (open to any type of entity, subject to any clarifications in the full announcement). Key administrative details in the source listing include the opportunity number W81XWH-21-PRORP-CTA, administering agency listed as the Department of Defense / Department of the Army (USAMRAA), a creation date of April 1, 2021, an original closing date of September 10, 2021, and an intent that awards be made no later than September 30, 2022. Like many DoD opportunities, actual funding depends on federal fund availability and on scientific and programmatic review outcomes. The funds anticipated for awards are FY21 funds with a use expiration of September 30, 2027, which matters for project planning and the timing of expenditures.

Overall, the PRORP Clinical Trial Award is best understood as a trial-startup-and-execution mechanism aimed at high-impact, near-term orthopaedic solutions for warfighter and Veteran needs. It prioritizes readiness and return-to-function outcomes, demands convincing preliminary evidence and a strong operational plan, and expects applicants to be prepared for real regulatory, data, safety, and monitoring obligations typical of FDA-relevant clinical trials.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Orthopaedic, Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 01, 2021.
• Applicants must submit their applications by Sep 10, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 PRORP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: